Literature DB >> 12088665

2001: a year of major advances in anthrax toxin research.

Michael Mourez1, D Borden Lacy, Kristina Cunningham, Rachel Legmann, Bret R Sellman, Jeremy Mogridge, R John Collier.   

Abstract

Anthrax is caused when spores of Bacillus anthracis enter a host and germinate. The bacteria multiply and secrete a tripartite toxin causing local edema and, in systemic infection, death. In nature, anthrax is primarily observed in cattle and other herbivores; humans are susceptible but rarely affected. In 2001, anthrax spores were used effectively for the first time in bioterrorist attacks, resulting in 11 confirmed cases of human disease and five deaths. These events have underscored the need for improved prophylaxis, therapeutics and a molecular understanding of the toxin. The good news about anthrax is that several decisive discoveries regarding the toxin have been reported recently. Most notably, the toxin receptor was identified, the 3-D structures of two of the toxin subunits were solved and potent in vivo inhibitors were designed. These findings have improved our understanding of the intoxication mechanism and are stimulating the design of strategies to fight disease in the future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088665     DOI: 10.1016/s0966-842x(02)02369-7

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  24 in total

1.  Characterization of dominant-negative forms of anthrax protective antigen.

Authors:  Ming Yan; R John Collier
Journal:  Mol Med       Date:  2003 Jan-Feb       Impact factor: 6.354

2.  Binding and internalization of Clostridium perfringens iota-toxin in lipid rafts.

Authors:  Masahiro Nagahama; Akiwo Yamaguchi; Tohko Hagiyama; Noriko Ohkubo; Keiko Kobayashi; Jun Sakurai
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

Review 3.  The Molecular Basis of Toxins' Interactions with Intracellular Signaling via Discrete Portals.

Authors:  Adi Lahiani; Ephraim Yavin; Philip Lazarovici
Journal:  Toxins (Basel)       Date:  2017-03-16       Impact factor: 4.546

4.  Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication.

Authors:  Steven M Opal; Andrew W Artenstein; Patricia A Cristofaro; Jhung W Jhung; John E Palardy; Nicholas A Parejo; Yow-Pin Lim
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Importance of srtA and srtB for growth of Bacillus anthracis in macrophages.

Authors:  Steven D Zink; Drusilla L Burns
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

7.  Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.

Authors:  Yuequan Shen; Natalia L Zhukovskaya; Michael I Zimmer; Sandriyana Soelaiman; Pamela Bergson; Chyung-Ru Wang; Craig S Gibbs; Wei-Jen Tang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-20       Impact factor: 11.205

8.  Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.

Authors:  Sha Cao; Aizhen Guo; Ziduo Liu; Yadi Tan; Gaobing Wu; Chengcai Zhang; Yaxing Zhao; Huanchun Chen
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

9.  Bacillus anthracis lethal toxin represses MMTV promoter activity through transcription factors.

Authors:  Zhigang Kang; Jeanette I Webster Marketon; Antoinette Johnson; Esther M Sternberg
Journal:  J Mol Biol       Date:  2009-04-21       Impact factor: 5.469

10.  Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin.

Authors:  Bin Zhou; Charlotte Carney; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2007-11-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.